Skip to main content

stock

MTRI · InMed Pharmaceuticals Inc.

Insiders net bought $34,572 in 90 days; last 8-K filed Nov 16: acquisition or sale completed, results.

Follow MTRI free

Price

Loading the MTRI chart…

Chart by TradingView

The business

What the company does and what it reports, from its SEC filings.

What it is

We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs.

From the 10-K for the fiscal year ended Jun 30, 2026, filed Sep 9, 2026.

Read the 10-K on SEC
Sector
Life Sciences (SEC office)
Industry
Pharmaceutical Preparations (SIC 2834)
Employees
Not stated in the 10-K.
Headquarters
Vancouver
Incorporated in
British Columbia, Canada
Fiscal year ends
June
Exchange
Nasdaq
Fractional shares
No
Listed options
No
Filer category
<br>Emerging growth company
Shares outstanding
5,493,735 as of Oct 30, 2026 (XBRL frame )
Filer (SEC EDGAR)
EDGAR filing index

Key stats

Valuation and the ratios that use the live price are free with an account.

Start free to see this

Deep value

NCAV
-$1.24M
NCAV per share
-$0.23
NNWC
-$1.41M
NNWC per share
-$0.26

Expectations

Free cash flow
—
Free cash growth, last 5 years
—
Revenue growth, last 5 years
—

Margins

Gross
29.7%
Operating
—
Net
—

Returns

ROE
—
ROA
-1008.1%

Health

Current ratio
—
Debt/equity
—

Trailing twelve months to Sep 30, 2026; balance sheet at Sep 30, 2026.

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
Sep 30, 2026———-$2.33M
10-Q filed Nov 3, 2026
Jun 30, 2026———-$5.84M
S-4/A filed Sep 29, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Mar 31, 2026———-$2.97M
S-4 filed Jul 2, 2026
Dec 31, 2025$820,188$184,194—-$2.03M
S-4 filed Jul 2, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Sep 30, 2025$1.12M$403,159—-$1.73M
10-Q filed Nov 3, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Jun 30, 2025$1.30M$576,654—$4.67M
10-Q filed Nov 3, 2026
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
Mar 31, 2025$1.26M$175,625—-$2.12M
S-4 filed Jul 2, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Dec 31, 2024$1.11M$460,894—-$2.58M
S-4 filed Jul 2, 2026
Assembled from more than one filing; the filing above is only the newest of them.
Cash
$1.09M
Debt
—
Net cash
—
Current assets
$1.26M
Current liabilities
—
Working capital
—
Total liabilities
$2.51M
Assets
$1.31M
Equity
-$1.20M

Balance as of Sep 30, 2026.

SEC data as of Nov 17, 2026

Earnings moves

ReportReaction day
Nov 16, 2026 Before the openNov 16, 2026

How the price moved after each report: Start free to see this

What happened after past reports, not a forecast. Report dates from SEC 8-K results filings (Item 2.02) since Oct 6, 2025; moves from daily closes.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
Jun 30, 2026——-$12.56M—
Jun 30, 2025$4.94M—-$1.70M-$8.10M
Jun 30, 2024$4.60M—-$7.68M-$7.00M
Jun 30, 2023$1.37M-$7.95M-$7.95M-$7.44M
Jun 30, 2022$1.37M-$18.60M-$18.60M-$15.62M
Jun 30, 2021$1.90M-$10.20M-$10.20M-$9.79M
Jun 30, 2020——-$8.94M-$7.42M

What it filed

Material events and 5% ownership filings from the last year.

Company filings

since Fri Mar 20 · 3 offering filings in 12 months · since Fri Apr 3

events

  • Acquisition or sale completedResults
    Nov 168-K
  • Material agreementAcquisition or sale completedResultsUnregistered share saleShareholder rights changedChange in controlExecutive or director changeBylaws or fiscal year changeItem 5.05Item 5.06

    CEO succession, abrupt

    Nov 108-K
  • Regulation FD disclosure
    Nov 98-K
  • Regulation FD disclosure
    Nov 58-K
  • Bylaws or fiscal year changeShareholder vote resultsOther event
    Nov 58-K
  • Regulation FD disclosure
    Nov 38-K

5% owners ()

Owners and trading

Insider, politician and fund moves, short interest, and the volume traded off the exchange.

Insiders, politicians and funds

Insider trades, last 90 days

  • ADAR1 Capital Management, LLC

    10% owner

    Buy$34,572

    Nov 9, 8:18 PM ET

All insider trades for MTRI

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

None of the tracked funds held this at their last 13F.

Short interest

Hard to borrow: Alpaca will not lend it for shorting

Off-exchange short volume, 20 days

28.7%

Through Nov 16, 2026

Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.

Short interest and short volume: FINRA

Off-exchange and dark pools

No off-exchange data

FINRA has no off-exchange data for MTRI yet.

Members see

  • Signals: which strategies fired on MTRI, and the evidence behind each
  • Options positioning: the levels dealers are hedged around
  • Technicals: trend and momentum readings
  • Earnings moves: how the price moved after each report
  • News: stories counted once across outlets
Start free to see these

Comments · 0

No comments yet.

Be the first to say something about MTRI.

nakagai

Signals on MTRI come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Follow MTRI free

Not financial advice. Read the terms that govern posting here.